TY - JOUR
T1 - The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin
AU - MOBILE Study Group
AU - Aleppo, Grazia
AU - Beck, Roy W.
AU - Bailey, Ryan
AU - Ruedy, Katrina J.
AU - Calhoun, Peter
AU - Peters, Anne L.
AU - Pop-Busui, Rodica
AU - Philis-Tsimikas, Athena
AU - Bao, Shichun
AU - Umpierrez, Guillermo
AU - Davis, Georgia
AU - Kruger, Davida
AU - Bhargava, Anuj
AU - Young, Laura
AU - Buse, John B.
AU - McGill, Janet B.
AU - Martens, Thomas
AU - Nguyen, Quang T.
AU - Orozco, Ian
AU - Biggs, William
AU - Lucas, K. Jean
AU - Polonsky, William H.
AU - Price, David
AU - Bergenstal, Richard M.
N1 - Publisher Copyright:
© 2021 by the American Diabetes Association.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - OBJECTIVE To explore the effect of discontinuing continuous glucose monitoring (CGM) after 8 months of CGM use in adults with type 2 diabetes treated with basal without bolus insulin. RESEARCH DESIGN AND METHODS This multicenter trial had an initial randomization to either real-time CGM or blood glucose monitoring (BGM) for 8 months followed by 6 months in which the BGM group continued to use BGM (n = 57) and the CGM group was randomly reassigned either to continue CGM (n = 53) or discontinue CGM with resumption of BGM for glucose monitoring (n = 53). RESULTS In the group that discontinued CGM, mean time in range (TIR) 70–180 mg/dL, which improved from 38% before initiating CGM to 62% after 8 months of CGM, decreased after discontinuing CGM to 50% at 14 months (mean change from 8 to 14 months-12% [95% CI-21% to-3%], P = 0.01). In the group that continued CGM use, little change was found in TIR from 8 to 14 months (baseline 44%, 8 months 56%, 14 months 57%, mean change from 8 to 14 months 1% [95% CI-11% to 12%], P = 0.89). Comparing the two groups at 14 months, the adjusted treatment group difference in mean TIR was-6% (95% CI-16% to 4%, P = 0.20). CONCLUSIONS In adults with type 2 diabetes treated with basal insulin who had been using real-time CGM for 8 months, discontinuing CGM resulted in a loss of about one-half of the initial gain in TIR that had been achieved during CGM use.
AB - OBJECTIVE To explore the effect of discontinuing continuous glucose monitoring (CGM) after 8 months of CGM use in adults with type 2 diabetes treated with basal without bolus insulin. RESEARCH DESIGN AND METHODS This multicenter trial had an initial randomization to either real-time CGM or blood glucose monitoring (BGM) for 8 months followed by 6 months in which the BGM group continued to use BGM (n = 57) and the CGM group was randomly reassigned either to continue CGM (n = 53) or discontinue CGM with resumption of BGM for glucose monitoring (n = 53). RESULTS In the group that discontinued CGM, mean time in range (TIR) 70–180 mg/dL, which improved from 38% before initiating CGM to 62% after 8 months of CGM, decreased after discontinuing CGM to 50% at 14 months (mean change from 8 to 14 months-12% [95% CI-21% to-3%], P = 0.01). In the group that continued CGM use, little change was found in TIR from 8 to 14 months (baseline 44%, 8 months 56%, 14 months 57%, mean change from 8 to 14 months 1% [95% CI-11% to 12%], P = 0.89). Comparing the two groups at 14 months, the adjusted treatment group difference in mean TIR was-6% (95% CI-16% to 4%, P = 0.20). CONCLUSIONS In adults with type 2 diabetes treated with basal insulin who had been using real-time CGM for 8 months, discontinuing CGM resulted in a loss of about one-half of the initial gain in TIR that had been achieved during CGM use.
UR - https://www.scopus.com/pages/publications/85120855275
U2 - 10.2337/dc21-1304
DO - 10.2337/dc21-1304
M3 - Article
C2 - 34588210
AN - SCOPUS:85120855275
SN - 0149-5992
VL - 44
SP - 2729
EP - 2737
JO - Diabetes care
JF - Diabetes care
IS - 12
ER -